Method of administering amantadine prior to a sleep period
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/22
A61K-009/48
A61K-031/13
A61K-009/00
출원번호
US-0428899
(2017-02-09)
등록번호
US-9867791
(2018-01-16)
발명자
/ 주소
Went, Gregory T.
Sathyan, Gayatri
Vermani, Kavita
Ganapati, Gangadhara
Coffee, Michael
Shek, Efraim
Katdare, Ashok
출원인 / 주소
Adamas Pharma, LLC
대리인 / 주소
Cooley LLP
인용정보
피인용 횟수 :
3인용 특허 :
112
초록
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
대표청구항▼
1. A method of administering a dose of a pharmaceutical composition of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof to a human patient in need thereof, comprising administering said dose of said pharmaceutical composition to said human patient
1. A method of administering a dose of a pharmaceutical composition of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof to a human patient in need thereof, comprising administering said dose of said pharmaceutical composition to said human patient orally, once daily 0 to 4 hours before bedtime, wherein said dose of said pharmaceutical composition comprises: (i) 250 mg to 600 mg of the drug; and (ii) one or more excipients, wherein at least one of said one or more excipients modifies the release of said drug to provide an extended release dosage form, and wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the fractional AUC0-4 for amantadine is less than 5% of AUC0-inf and the Tmax of amantadine is 8 to 20 hours. 2. A method of administering a dose of a pharmaceutical composition of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof to a human patient in need thereof, comprising administering said dose of said pharmaceutical composition to said human patient orally, once daily 0 to 4 hours before bedtime, wherein said dose of said pharmaceutical composition comprises: (i) 250 mg to 600 mg of the drug; and (ii) one or more excipients, wherein at least one of said one or more excipients modifies the release of said drug to provide an extended release dosage form, and wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the fractional AUC0-8 for amantadine is 5% to 15% of AUC0-inf and the Tmax for amantadine is 8 to 20 hours. 3. A method of administering a dose of a pharmaceutical composition of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof to a human patient in need thereof, comprising administering said dose of said pharmaceutical composition to said human patient orally, once daily 0 to 4 hours before bedtime, wherein said dose of said pharmaceutical composition comprises: (i) 250 mg to 600 mg of the drug; and (ii) one or more excipients, wherein at least one of said one or more excipients modifies the release of said drug to provide an extended release dosage form, and wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the fractional AUC0-4 for amantadine is less than 5% of AUC0-inf and the Cmax for amantadine is 1.0 to 2.4 ng/ml per mg of amantadine. 4. A method of administering a dose of a pharmaceutical composition of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof to a human patient in need thereof, comprising administering said dose of said pharmaceutical composition to said human patient orally, once daily 0 to 4 hours before bedtime, wherein said dose of said pharmaceutical composition comprises: (i) 250 mg to 600 mg of the drug; and (ii) one or more excipients, wherein at least one of said one or more excipients modifies the release of said drug to provide an extended release dosage form, and wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the fractional AUC0-8 for amantadine is 5% to 15% of AUC0-inf and the Cmax for amantadine is 1.0 to 2.4 ng/ml per mg of amantadine. 5. The method of claim 1, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the Cmax for amantadine is 1.0 to 2.4 ng/ml per mg of amantadine. 6. The method of claim 1, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the AUC0-inf for amantadine is 40 to 75 ng*h/ml per mg of amantadine. 7. The method of claim 5, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the AUC0-inf for amantadine is 40 to 75 ng*h/ml per mg of amantadine. 8. The method of claim 1, wherein when said pharmaceutical composition is dosed in a multiple dose, fasted, human pharmacokinetic study in healthy subjects, the steady state AUC0-24 for amantadine is 44 to 83 ng*h/ml per mg of amantadine. 9. The method of claim 5, wherein when said pharmaceutical composition is dosed in a multiple dose, fasted, human pharmacokinetic study in healthy subjects, the steady state AUC0-24 for amantadine is 44 to 83 ng*h/ml per mg of amantadine. 10. The method of claim 1, wherein said patient is being treated for Parkinson's disease. 11. The method of claim 5, wherein said patient is being treated for Parkinson's disease. 12. The method of claim 8, wherein said patient is being treated for Parkinson's disease. 13. The method of claim 10, wherein said patient suffers from levodopa-induced dyskinesia. 14. The method of claim 13, wherein the method reduces the frequency or severity of levodopa-induced dyskinesia in said patient. 15. The method of claim 1, wherein said dose of said pharmaceutical composition comprises 1 or 2 unit dosage forms. 16. The method of claim 15, wherein said unit dosage form comprises a capsule. 17. The method of claim 2, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the Cmax for amantadine is 1.0 to 2.4 ng/ml per mg of amantadine. 18. The method of claim 2, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the AUC0-inf for amantadine is 40 to 75 ng*h/ml per mg of amantadine. 19. The method of claim 17, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the AUC0-inf for amantadine is 40 to 75 ng*h/ml per mg of amantadine. 20. The method of claim 2, wherein when said pharmaceutical composition is dosed in a multiple dose, fasted, human pharmacokinetic study in healthy subjects, the steady state AUC0-24 for amantadine is 44 to 83 ng*h/ml per mg of amantadine. 21. The method of claim 17, wherein when said pharmaceutical composition is dosed in a multiple dose, fasted, human pharmacokinetic study in healthy subjects, the steady state AUC0-24 for amantadine is 44 to 83 ng*h/ml per mg of amantadine. 22. The method of claim 2, wherein said patient is being treated for Parkinson's disease. 23. The method of claim 17, wherein said patient is being treated for Parkinson's disease. 24. The method of claim 20, wherein said patient is being treated for Parkinson's disease. 25. The method of claim 22, wherein said patient suffers from levodopa-induced dyskinesia. 26. The method of claim 25, wherein the method reduces the frequency or severity of levodopa-induced dyskinesia in said patient. 27. The method of claim 2, wherein said dose of said pharmaceutical composition comprises 1 or 2 unit dosage forms. 28. The method of claim 27, wherein said unit dosage form comprises a capsule. 29. The method of claim 3, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the AUC0-inf for amantadine is 40 to 75 ng*h/ml per mg of amantadine. 30. The method of claim 3, wherein when said pharmaceutical composition is dosed in a multiple dose, fasted, human pharmacokinetic study in healthy subjects, the steady state AUC0-24 for amantadine is 44 to 83 ng*h/ml per mg of amantadine. 31. The method of claim 3, wherein said patient is being treated for Parkinson's disease. 32. The method of claim 29, wherein said patient is being treated for Parkinson's disease. 33. The method of claim 31, wherein said patient suffers from levodopa-induced dyskinesia. 34. The method of claim 33, wherein the method reduces the frequency or severity of levodopa-induced dyskinesia in said patient. 35. The method of claim 3, wherein said dose of said pharmaceutical composition comprises 1 or 2 unit dosage forms. 36. The method of claim 35, wherein said unit dosage form comprises a capsule. 37. The method of claim 4, wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the AUC0-inf for amantadine is 40 to 75 ng*h/ml per mg of amantadine. 38. The method of claim 4, wherein when said pharmaceutical composition is dosed in a multiple dose, fasted, human pharmacokinetic study in healthy subjects, the steady state AUC0-24 for amantadine is 44 to 83 ng*h/ml per mg of amantadine. 39. The method of claim 4, wherein said patient is being treated for Parkinson's disease. 40. The method of claim 37, wherein said patient is being treated for Parkinson's disease. 41. The method of claim 39, wherein said patient suffers from levodopa-induced dyskinesia. 42. The method of claim 41, wherein the method reduces the frequency or severity of levodopa-induced dyskinesia in said patient. 43. The method of claim 4, wherein said dose of said pharmaceutical composition comprises 1 or 2 unit dosage forms. 44. The method of claim 43, wherein said unit dosage form comprises a capsule. 45. The method of claim 1, wherein said fractional AUC0-4 for amantadine, said AUC0-inf for amantadine and said Tmax for amantadine are determined from one subject of said human pharmacokinetic study. 46. The method of claim 1, wherein said fractional AUC0-4 for amantadine and said AUC0-inf for amantadine are mean values determined from said human pharmacokinetic study, and said Tmax for amantadine is the median value determined from said human pharmacokinetic study. 47. The method of claim 2, wherein said fractional AUC0-8 for amantadine, said AUC0-inf for amantadine, and said Tmax for amantadine are determined from one subject of said human pharmacokinetic study. 48. The method of claim 2, wherein said fractional AUC0-8 for amantadine and said AUC0-inf for amantadine are mean values determined from said human pharmacokinetic study, and said Tmax for amantadine is the median value determined from said human pharmacokinetic study. 49. The method of claim 3, wherein said fractional AUC0-4 for amantadine, said AUC0-inf for amantadine, and said Cmax for amantadine are determined from one subject of said human pharmacokinetic study. 50. The method of claim 3, wherein said fractional AUC0-4 for amantadine, said AUC0-inf for amantadine, and said Cmax for amantadine are mean values determined from said human pharmacokinetic study. 51. The method of claim 4, wherein said fractional AUC0-8 for amantadine, said AUC0-inf for amantadine, and said Cmax for amantadine are determined from one subject of said human pharmacokinetic study. 52. The method of claim 4, wherein said fractional AUC0-8 for amantadine, said AUC0-inf for amantadine, and said Cmax for amantadine are mean values determined from said human pharmacokinetic study. 53. The method of claim 1, wherein said pharmaceutical composition is selected from the group consisting of one unit dosage form comprising 340 mg of said drug and two unit dosage forms each comprising 170 mg of said drug. 54. The method of claim 2, wherein said pharmaceutical composition is selected from the group consisting of one unit dosage form comprising 340 mg of said drug and two unit dosage forms each comprising 170 mg of said drug. 55. The method of claim 3, wherein said pharmaceutical composition is selected from the group consisting of one unit dosage form comprising 340 mg of said drug and two unit dosage forms each comprising 170 mg of said drug. 56. The method of claim 4, wherein said pharmaceutical composition is selected from the group consisting of one unit dosage form comprising 340 mg of said drug and two unit dosage forms each comprising 170 mg of said drug.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (112)
Kelleher Judith A. ; Maples Kirk R. ; Dykman Alina ; Zhang Yong-Kang ; Wilcox Allan L. ; Levell Julian, .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing the same.
Bormann Joachim (Frankfurt DEX) Gold Markus R. (Nauheim DEX) Schatton Wolfgang (Eschborn DEX), Adamantane derivatives in the prevention and treatment of cerebral ischemia.
Rudnic Edward M. ; Belendiuk George W. ; McCarty John ; Wassink Sandra ; Couch Richard A., Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
Guittard George V. (Cupertino CA) Wong Patrick S. L. (Palo Alto CA) Kuczynski Anthony L. (Mountain View CA) Kidney David J. (Palo Alto CA), Antiviral therapy.
Elger Gordon A. (Huntingdon GBX) Leslie Stewart T. (Cambridge GBX) Malkowska Sandra T. A. (Landbeach GBX) Miller Ronald B. (Basel CHX) Neale Philip J. (Cambridge GBX), Controlled release pharmaceutical composition.
Yang S. Shirley (Succasunna NJ) Boisvert Wayne (Randolph NJ) Muhammad Nouman A. (Long Valley NJ) Weiss Jay (East Brunswick NJ), Controlled release tacrine drug delivery systems and methods for preparing same.
Wong, Patrick S. L.; Dong, Liang C.; Wan, Jiansheng, Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Vaya, Navin; Karan, Rajesh Singh; Nadkarni, Sunil Sadanand; Gupta, Vinod Kumar, Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form for treating central nervous system disorders.
Edgren David E. (El Granada CA) Carpenter Howard A. (Palo Alto CA) Bhatti Gurdish K. (Fremont CA) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Nrnberg Eberhard (Uttenreuth/Welher DEX) Seiller Erhard (Nidderau DEX) Ritsert Stefan (Eberbach DEX), Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production there.
Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Weyers, Richard G.; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Hatamkhany, Zah, Methods and devices for providing prolonged drug therapy.
Chen, Guohua; Lautenbach, Scott D.; Dionne, Keith E.; Jordan, Scott D.; Berry, Steve A.; Rodenberger, Craig I.; Ayer, Rupal, Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems.
Buxton Ian R. (Cambridge GBX) Critchley Helen (Cambridge GBX) Leslie Stewart T. (Cambridge GBX) Prater Derek A. (Cambridge GBX) Miller Ronald B. (Basle CHX) Malkowska Sandra T. A. (Cambridge GBX), Pharmaceutical spheroid formulation.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Peery, John R.; Dionne, Keith E.; Eckenhoff, James B.; Landrau, Felix A.; Lautenbach, Scott D.; Magruder, Judy A.; Wright, Jeremy C., Sustained delivery of an active agent using an implantable system.
Hanns Ludwig DE; Detlef Dietrich DE; Hinderk M. Emrich DE; Liv Bode DE, USE OF ADAMANTANE AMINES OR STRUCTURALLY SIMILAR COMPOUNDS FOR COMBATING BORNA DISEASE VIRUS AND FOR THE PREVENTION AND TREATMENT OF AFFECTIVE DISEASES AND OTHER DISORDERS ASSOCIATED WITH BDV INFECTI.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.